/
/
/

Piramal Pharma Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021
₹2270 Cr₹2752 Cr₹2140 Cr₹2044 Cr₹1934 Cr₹2754 Cr₹2204 Cr₹2242 Cr₹1951 Cr₹2552 Cr₹1959 Cr₹1911 Cr₹1749 Cr₹2164 Cr₹1716 Cr₹1720 Cr₹1482 Cr₹2131 Cr₹1539 Cr₹1578 Cr
₹89 Cr₹46 Cr₹43 Cr₹66 Cr₹58 Cr₹42 Cr₹12 Cr₹61 Cr₹20 Cr₹26 Cr₹62 Cr₹49 Cr₹38 Cr₹25 Cr₹83 Cr₹46 Cr₹72 Cr₹78 Cr₹161 Cr₹18 Cr
₹2359 Cr₹2798 Cr₹2183 Cr₹2109 Cr₹1992 Cr₹2796 Cr₹2216 Cr₹2303 Cr₹1971 Cr₹2579 Cr₹2020 Cr₹1961 Cr₹1787 Cr₹2188 Cr₹1799 Cr₹1766 Cr₹1554 Cr₹2210 Cr₹1700 Cr₹1595 Cr
₹2298 Cr₹2510 Cr₹2157 Cr₹2088 Cr₹2024 Cr₹2436 Cr₹2063 Cr₹2092 Cr₹1931 Cr₹2219 Cr₹1877 Cr₹1830 Cr₹1790 Cr₹1997 Cr₹1793 Cr₹1714 Cr₹1627 Cr₹1899 Cr₹1461 Cr₹1519 Cr
₹285 Cr₹507 Cr₹239 Cr₹224 Cr₹165 Cr₹603 Cr₹350 Cr₹403 Cr₹224 Cr₹556 Cr₹330 Cr₹315 Cr₹171 Cr₹376 Cr₹170 Cr₹219 Cr₹89 Cr₹476 Cr₹386 Cr₹214 Cr
₹88 Cr₹83 Cr₹89 Cr₹82 Cr₹86 Cr₹104 Cr₹103 Cr₹108 Cr₹107 Cr₹114 Cr₹106 Cr₹110 Cr₹119 Cr₹104 Cr₹95 Cr₹83 Cr₹62 Cr₹57 Cr₹50 Cr₹49 Cr
-₹27 Cr₹29 Cr-₹104 Cr-₹61 Cr-₹98 Cr₹257 Cr₹50 Cr₹103 Cr-₹67 Cr₹215 Cr₹5 Cr₹20 Cr-₹122 Cr₹87 Cr-₹89 Cr-₹37 Cr-₹135 Cr₹254 Cr₹189 Cr₹27 Cr
-₹89 Cr-₹22 Cr-₹146 Cr-₹114 Cr-₹100 Cr₹137 Cr-₹13 Cr₹5 Cr-₹111 Cr₹89 Cr-₹4 Cr-₹14 Cr-₹113 Cr₹42 Cr-₹106 Cr-₹48 Cr-₹129 Cr₹185 Cr₹154 Cr₹20 Cr

Share Price Live Stats

Open (₹)214.99
Volume (₹)26.18 L
High (₹)217.00
Upper Circuit257.38
Low (₹)210.52
Lower Circuit171.60
Prev Close214.49
52W High (₹)220.36
Price214.22
52W Low (₹)132.30

Share Market Cap & Key Ratios Overview

M.Cap (₹)28550.80 Cr
Div. Yield (%)0.00
PE Ratio0.00
Debt to Equity0.68
Price to Book2.24
Book Value60.96
EPS (TTM)-2.36
Face Value10.00
ROE (%)-4.04

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
PPLPHARMANSE
LTP
1W Low
1W High
Market cap (₹)
1899-21 (-1.09%)
1895
1984.80
4,56,833Cr
9100-139 (-1.50%)
9087
9467
2,45,426Cr
4857-193 (-3.82%)
4823
5066
1,87,320Cr
1120-71 (-5.96%)
1120
1187
1,13,217Cr
1385-38.5 (-2.70%)
1375.50
1426.10
1,12,212Cr
1840-98.5 (-5.08%)
1811.70
1949
1,01,155Cr
2110-61.5 (-2.83%)
2100.60
2192
97,626Cr
2327.9-55 (-2.31%)
2317
2419.20
96,859Cr
1151-27 (-2.29%)
1151
1179.90
96,406Cr
1653.1+7.8 (0.47%)
1622.60
1717
93,614Cr
214.22-4.46 (-2.04%)
210.50
218.61
28,551Cr

Key Highlights of Piramal Pharma Ltd’s P&L

In 2026-03-31, Piramal Pharma Ltd reported total revenue of ₹9111.51Cr, compared with ₹9312.95Cr in 2025-03-31, reflecting Piramal Pharma Ltd turnover.

Depreciation was ₹831.24Cr and finance costs were ₹340.8Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹-₹176.06Cr in 2026-03-31 as compared to ₹414.64Cr in 2025-03-31.

Net Profit (PAT) was ₹-₹325.94Cr in 2026-03-31 compared with ₹91.13Cr in 2025-03-31.

Earnings per share (EPS) were ₹-2.46 in 2026-03-31, compared with ₹0.69 in 2025-03-31.